The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing author
Tweet Content
The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing authorisation of deucravacitinib (Sotyktu) in the treatment of moderate to severe psoriasis based on the POETYK PSO-1 & POETYK PSO-2 RCTs https://t.co/KBIYSJVFqu
. https://t.co/nzuHh6v0ua
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off